Leucht Stefan, Samara Myrto, Heres Stephan, Patel Maxine X, Furukawa Toshi, Cipriani Andrea, Geddes John, Davis John M
Department of Psychiatry and Psychotherapy, Technische Universität München Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany; Institute of Psychiatry, Psychology and Neuroscience, King's College London, Department of Psychosis Studies, London, UK;
Department of Psychiatry and Psychotherapy, Technische Universität München Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany;
Schizophr Bull. 2015 Nov;41(6):1397-402. doi: 10.1093/schbul/sbv037. Epub 2015 Apr 3.
The concept of dose equivalence is important for many purposes. The classical approach published by Davis in 1974 subsequently dominated textbooks for several decades. It was based on the assumption that the mean doses found in flexible-dose trials reflect the average optimum dose which can be used for the calculation of dose equivalence. We are the first to apply the method to second-generation antipsychotics.
We searched for randomized, double-blind, flexible-dose trials in acutely ill patients with schizophrenia that examined 13 oral second-generation antipsychotics, haloperidol, and chlorpromazine (last search June 2014). We calculated the mean doses of each drug weighted by sample size and divided them by the weighted mean olanzapine dose to obtain olanzapine equivalents.
We included 75 studies with 16 555 participants. The doses equivalent to 1 mg/d olanzapine were: amisulpride 38.3 mg/d, aripiprazole 1.4 mg/d, asenapine 0.9 mg/d, chlorpromazine 38.9 mg/d, clozapine 30.6 mg/d, haloperidol 0.7 mg/d, quetiapine 32.3mg/d, risperidone 0.4 mg/d, sertindole 1.1 mg/d, ziprasidone 7.9 mg/d, zotepine 13.2 mg/d. For iloperidone, lurasidone, and paliperidone no data were available.
The classical mean dose method is not reliant on the limited availability of fixed-dose data at the lower end of the effective dose range, which is the major limitation of "minimum effective dose methods" and "dose-response curve methods." In contrast, the mean doses found by the current approach may have in part depended on the dose ranges chosen for the original trials. Ultimate conclusions on dose equivalence of antipsychotics will need to be based on a review of various methods.
剂量等效性的概念在许多方面都很重要。戴维斯于1974年发表的经典方法随后几十年一直主导着教科书。它基于这样一种假设,即在灵活剂量试验中发现的平均剂量反映了可用于计算剂量等效性的平均最佳剂量。我们是首个将该方法应用于第二代抗精神病药物的研究团队。
我们检索了针对急性精神分裂症患者的随机、双盲、灵活剂量试验,这些试验涉及13种口服第二代抗精神病药物、氟哌啶醇和氯丙嗪(最后一次检索时间为2014年6月)。我们计算了每种药物按样本量加权后的平均剂量,并将其除以加权后的奥氮平平均剂量,以获得奥氮平等效剂量。
我们纳入了75项研究,共16555名参与者。相当于1mg/d奥氮平的剂量分别为:氨磺必利38.3mg/d、阿立哌唑1.4mg/d、阿塞那平0.9mg/d、氯丙嗪38.9mg/d、氯氮平30.6mg/d、氟哌啶醇0.7mg/d、喹硫平32.3mg/d、利培酮0.4mg/d、舍吲哚1.1mg/d、齐拉西酮7.9mg/d、佐替平13.2mg/d。对于伊潘立酮、鲁拉西酮和帕利哌酮,没有可用数据。
经典的平均剂量方法不依赖于有效剂量范围下限固定剂量数据的有限可用性,这是“最小有效剂量方法”和“剂量反应曲线方法”的主要局限性。相比之下,当前方法所发现的平均剂量可能部分取决于原始试验所选择的剂量范围。关于抗精神病药物剂量等效性的最终结论将需要基于对各种方法的综述。